|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Investments: | |||||||||||||||
| Fixed maturity securities, available-for-sale, at fair value (net of allowance for credit losses of $6,228 and $7,000, respectively) (amortized cost of $2,206,626 and $1,848,755, respectively) | |||||||||||||||
| Fixed maturity securities, held-to-maturity, at amortized cost (net of allowance for credit losses of $2,256 and $468, respectively) | |||||||||||||||
| Equity securities, at fair value | |||||||||||||||
| Mortgage loans, at fair value | |||||||||||||||
| Equity method investments | |||||||||||||||
| Other long-term investments | |||||||||||||||
| Short-term investments, at fair value | |||||||||||||||
| Total investments | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Restricted cash | |||||||||||||||
| Funds at Lloyd's | |||||||||||||||
| Options, at fair value | |||||||||||||||
| Premiums and commissions receivable, net | |||||||||||||||
| Reinsurance recoverables, net | |||||||||||||||
| Ceded unearned premium | |||||||||||||||
| Deferred policy acquisition costs and VOBA | |||||||||||||||
| Deferred tax assets | |||||||||||||||
| Goodwill and intangible assets, net | |||||||||||||||
| Other assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and stockholders’ equity | |||||||||||||||
| Liabilities: | |||||||||||||||
| Reserves for losses and loss adjustment expenses | |||||||||||||||
| Unearned premiums | |||||||||||||||
| Deferred ceding commission | |||||||||||||||
| Reinsurance and premium payables | |||||||||||||||
| Funds held for others | |||||||||||||||
| Deferred tax liabilities | |||||||||||||||
| Accounts payable and accrued liabilities | |||||||||||||||
| Notes payable | |||||||||||||||
| Subordinated debt, net of debt issuance costs | |||||||||||||||
| Total liabilities | |||||||||||||||
| Stockholders’ equity | |||||||||||||||
| Series A preferred stock, $0.01 par value; 10,000,000 and 2,000,000 shares authorized, 0 and 1,969,660 shares issued and outstanding, respectively | |||||||||||||||
| Common stock, $0.01 par value, 500,000,000 shares authorized, 44,827,499 shares issued and 44,396,493 shares outstanding at June 30, 2026; 40,511,222 shares issued and outstanding at December 31, 2025 | |||||||||||||||
| Treasury stock, at cost, 431,006 and 0 shares, respectively | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Stock notes receivable | |||||||||||||||
| Accumulated other comprehensive (loss) income | |||||||||||||||
| Retained earnings | |||||||||||||||
| Total stockholders’ equity | |||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
